Herpes simplex virus (HSV)-specific proliferative and cytotoxic T-cell responses in humans immunized with an HSF type 2 glycoprotein subunit vaccine
Studies were undertaken to determine whether immunization of humans with a herpes simplex virus type 2 (HSV-2) glycoprotein-subunit vaccine would result in the priming of both HSV-specific proliferating cells and cytotoxic T cells. Peripheral blood lymphocytes (PBL) from all eight vaccinees studied responded by proliferating after stimulation with HSV-2, HSV-1, and glycoprotein gB-1. The PBL of five of these eight vaccinees proliferated following stimulation with gD-2, whereas stimulation with Gd-1 resulted in relatively low or no proliferative responses. T-cell clones were generated from HSV-2-stimulated PBL of three vaccinees who demonstrated strong proliferative responses to HSV-1 and HSV-2. Of 12 clones studied in lymphoproliferative assays, 9 were found to be cross-reactive for HSV-1 and HSV-2. Of the approximately 90 T-cell clones isolated, 14 demonstrated HSV-specific cytotoxic activity. Radioimmunoprecipitation-polyacrylamide gel electrophoresis analyses confirmed that the vaccinees had antibodies only to HSV glycoproteins, not to proteins which are absent in the subunit vaccine, indicating that these vaccinees had not become infected with HSV. Immunization of humans with an HSV-2 glycoprotein-subunit vaccine thus results in the priming of T cells that proliferate in response to stimulation with HSV and its glycoproteins and T cells that have cytotoxic activity against HSV-infected cells. Such HSV-specific memory T cells were detected as late as 2 years following the last boost with the subunit vaccine.
- Research Organization:
- Oncogen, Seattle, WA (USA)
- OSTI ID:
- 6399105
- Journal Information:
- J. Virol.; (United States), Vol. 62:12
- Country of Publication:
- United States
- Language:
- English
Similar Records
Expression of bovine herpesvirus 1 glycoproteins gI and gIII in transfected murine cells
Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques
Related Subjects
HERPES SIMPLEX
IMMUNOLOGY
LYMPHOCYTES
CELL PROLIFERATION
VIRUSES
RADIOIMMUNOASSAY
CELL KILLING
CHROMIUM 51
ELECTROPHORESIS
GLUCOPROTEINS
IMMUNITY
METHIONINE
SULFUR 35
THYMIDINE
TRITIUM COMPOUNDS
VACCINES
AMINO ACIDS
ANIMAL CELLS
AZINES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BIOLOGICAL MATERIALS
BLOOD
BLOOD CELLS
BODY FLUIDS
CARBOHYDRATES
CARBOXYLIC ACIDS
CHROMIUM ISOTOPES
CONNECTIVE TISSUE CELLS
DAYS LIVING RADIOISOTOPES
DISEASES
DRUGS
ELECTRON CAPTURE RADIOISOTOPES
EVEN-ODD NUCLEI
GLYCOPROTEINS
HETEROCYCLIC COMPOUNDS
IMMUNOASSAY
INFECTIOUS DISEASES
INTERMEDIATE MASS NUCLEI
ISOTOPE APPLICATIONS
ISOTOPES
LABELLED COMPOUNDS
LEUKOCYTES
LIGHT NUCLEI
LIPOTROPIC FACTORS
MATERIALS
MICROORGANISMS
NUCLEI
NUCLEOSIDES
NUCLEOTIDES
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANIC SULFUR COMPOUNDS
PARASITES
PROTEINS
PYRIMIDINES
RADIOASSAY
RADIOIMMUNOLOGY
RADIOISOTOPES
RIBOSIDES
SACCHARIDES
SKIN DISEASES
SOMATIC CELLS
SULFUR ISOTOPES
TRACER TECHNIQUES
VIRAL DISEASES
550701* - Microbiology- Tracer Techniques